Research

A phase 3 study to investigate the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) compared with placebo for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA.

The focus of this sub-study is to correlate baseline MRI findings with future events (e.g. covert brain infarction, recurrent strokes, intracranial bleeding), identify asundexian responders, further characterize the study population by MRI and add additional safety information on the asundexian 50 mg dose (to the Phase 2 study).

Study objective is to determine the effects of continuation vs. discontinuation of statins on the risk of ICH recurrence during 24 months of follow-up in patients presenting with a spontaneous lobar lCH while taking a statin drug. It also seeks to determine the effects of discontinuation vs. continuation of statins on the occurrence of major adverse cardiac and cerebrovascular events.

Saturn-MRI is an ancillary study to SATURN, to evaluate the effects of continuation vs. discontinuation of statin drugs on hemorrhagic and    ischemic MRI markers of cerebral small vessel disease, and whether the presence/burden of hemorrhagic markers on baseline MRI influences the risk of ICH recurrence on/off statin therapy.

A prospective cohort study of patients with acute ischemic stroke due to occlusion of the vertebral or basilar artery within 48-hours of symptom onset. Patients will undergo CT or MRI cerebral perfusion imaging prior to endovascular thrombectomy treatment. The results of this study will determine if cerebral perfusion imaging can identify a subset of patients who are most likely to have a favorable outcome after thrombectomy treatment.

The purpose of this study is to determine the efficacy of an investigational stroke sensor. The study device is manufactured by StrokeDx, Inc., a medical device company based in Pasadena, CA.